Synbiotic Health has acquired a 43,000 sqft facility in Madison, Wisconsin. The new facility is dedicated to the development and commercialisation of advanced probiotic ingredients for improved health.
The Madison facility, which is scheduled to come online in early 2023, will focus on scale-up and development of efficient commercial processes. It is designed to complement the company’s existing facilities in Lincoln, Nebraska, which are dedicated to the discovery of new probiotic strains. The Madison facility is being constructed specifically to support probiotics in a quality-focused, GMP environment that features very low humidity levels in all areas where probiotic ingredients will be found.
New lab space, which will have the capacity to accommodate numerous scientists, will allow Synbiotic Health to quickly screen new probiotics for growth and stability, thus increasing the company’s ability to introduce new high quality strains to the market.
Tim Brummels, President and CEO of Synbiotic Health, said: “This expansion of our capabilities is strategically aligned with the company’s goals. It brings our legacy of expertise in Nebraska, which is focused on discovery, to the next level. We are investing in the next phase of microbiome health: post-discovery development and commercialisation that will efficiently bring products to market.”
As evidence of the cutting-edge science the company is known for, Synbiotic Health was recently honored to be named the 2022 recipient of the Governor’s Bioscience Award, presented by Nebraska Governor Pete Ricketts. The Governor’s Bioscience Award is presented annually to an individual or company that has made significant contributions to Nebraska’s bioscience industry. The selection criteria range from conducting innovative research to product development to investment that grows the bioscience community in Nebraska.
In accepting the award, Mr. Brummels said: “We are proud to be able to take some of Nebraska’s leading academic science and turn it into innovative products that are unmatched in the global probiotics industry. We expect to deliver the same high level of scientific expertise at commercial scale from our new site in Madison.”
When fully operational in 2023, the Madison site is expected to employ a workforce of up to thirty-five employees, which will include technical, operations and administrative personnel. In addition to the R&D and commercial activities that will be operational at launch, the facility is expected to expand in the future with the addition of new services and capabilities that will provide added value to the dietary supplement market.
